Northland Capmk Forecasts MiMedx Group Q1 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Stock analysts at Northland Capmk issued their Q1 2025 earnings per share (EPS) estimates for MiMedx Group in a research report issued on Friday, December 27th. Northland Capmk analyst C. Byrnes forecasts that the company will earn $0.05 per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.09 EPS.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Price Performance

NASDAQ MDXG opened at $9.48 on Monday. The firm’s 50-day simple moving average is $8.35 and its two-hundred day simple moving average is $7.17. The company has a market cap of $1.39 billion, a PE ratio of 17.24 and a beta of 1.98. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

Institutional Trading of MiMedx Group

Hedge funds have recently modified their holdings of the company. Isthmus Partners LLC boosted its stake in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after buying an additional 91,714 shares during the period. Blue Trust Inc. bought a new stake in MiMedx Group during the third quarter valued at about $30,000. Point72 Asset Management L.P. bought a new position in MiMedx Group in the 2nd quarter valued at $40,000. Point72 DIFC Ltd boosted its holdings in shares of MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after buying an additional 4,275 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in shares of MiMedx Group in the 3rd quarter valued at approximately $64,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.